Exactly, the quarterly isn't going to be a saving grace here and...

Exactly, the quarterly isn't going to be a saving grace here and the selling is reflective of the severe diminishment of the SMB contract. What turns the ship is the replacement of the lost revenue base by new contracts. Every company has set backs, the other side of the rub with this issue is it being its a ling maw contract. If it was an issue with the neutraceutical side of the business I would be concerned.

This still an easy hold long term holders for who believe in the neutraceutical side of the business, as nothing has changed on that front. However I do believe the company will be under a bit of pressure now to get things moving on that front.